Vimarsana
Biggest News Aggregation in the World

Page 48 - Ipca Laboratories News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ipca Laboratories. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ipca Laboratories Today - Breaking & Trending Today

Coronavirus (COVID-19) Current Therapy Market Outlook Is Being Shaped By Antibody Therapy - Vimarsana News

Coronavirus (COVID-19) Current Therapy Market Outlook Is Being Shaped By Antibody Therapy

The Business Research Company’s COVID-19 Current Therapy Market 2022 – Opportunities And Strategies – Global Forecast To 2030

Ratlam: IPCA Laboratories awarded for environment protection - Vimarsana News

Ratlam: IPCA Laboratories awarded for environment protection

IPCA Ratlam unit head Dinesh Siyal informed that IPCA Laboratories invested Rs.40 crore last year under the environment head besides spending every year Rs 12 crore to Rs 14 crore for proper environment maintenance and management.

Stock markets open on a lacklustre note: Sensex up, Nifty above 16,200 - Vimarsana News

Stock markets open on a lacklustre note: Sensex up, Nifty above 16,200

Stock markets open on a lacklustre note: Sensex up, Nifty above 16,200

Coronavirus (COVID-19) Current Therapy Market Sees Antiviral Drugs Accounting For A Large Number Of Treatments - Vimarsana News

Coronavirus (COVID-19) Current Therapy Market Sees Antiviral Drugs Accounting For A Large Number Of Treatments

/PRNewswire/ -- Coronavirus (COVID-19) current therapy market segmentation is done by drug type into antiviral, monoclonal antibodies, corticosteroid,...

The Business Research Company: Coronavirus (COVID-19) Current Therapy Market Sees Antiviral Drugs Accounting For A Large Number Of Treatments - Vimarsana News

The Business Research Company: Coronavirus (COVID-19) Current Therapy Market Sees Antiviral Drugs Accounting For A Large Number Of Treatments

The COVID therapy market includes drugs in the form of antivirals, MAbs, and more. However, the market is set to see decline in the forecast period. LONDON, March 15, 2022 /PRNewswire/